hy, Achieving 5000kg Sales Volume of Probiotic Strain B2B

hy Central Research Institute exterior (Photo by hy)

[Asia Economy Reporter Seungjin Lee] Distribution specialist company hy announced on the 26th that it has achieved 5,000 kg in B2B (business-to-business) sales of probiotic strains. Since the business was fully launched in April last year, the cumulative sales volume has reached 8,000 kg. The 8,000 kg of strains is enough to produce more than 830 million units based on Yakult standards.

Strain B2B is hy's new growth engine. At the same time, it is a key business area for advancing as a distribution specialist company. It enables the enhancement of corporate image based on research and technological capabilities as well as the creation of new revenue streams.

hy is focusing on strengthening competitiveness in the B2B business. First, it expanded production facilities to meet the rapidly increasing demand. The number of freeze dryers, a core facility for strain powder production, was increased from 4 to 7 units. Monthly production volume increased by about 30%. To ensure smooth raw material supply, the company is considering building an additional production plant. In May, it launched the exclusive brand ‘hyLabs’.

Various transaction materials are also a strength. The country’s first skin probiotic ‘HY7714’ and body fat reduction probiotic ‘KillFat’ are core strains. In addition, it holds various officially recognized probiotics such as the vitamin B2 producing patented probiotic ‘HY7715’ and ‘HY8002’ isolated from the intestines of Koreans. Recently, it completed the development of natural fermented materials such as red ginseng and deer antler velvet.

It also exclusively sells overseas premium probiotics. It is ‘ME-3’ from France’s VF Bioscience. It has excellent glutathione production ability with outstanding antioxidant effects.

hy has built a library of over 4,800 strains. Continuous in-house screening and subsequent human application tests to verify probiotic functionality are underway, so the number of strains available for transactions is expected to increase further. The company is also planning systematic sales activities through the establishment of a dedicated B2B organization in the future.

Lee Jeong-yeol, head of hy’s Central Research Institute, said, “Through long-term investments since 2014, it has become possible to sell probiotic strains externally that were previously used only in our own products,” and added, “Since many companies including domestic pharmaceutical firms have requested raw material supply, we are confident that we will enter a high-growth trajectory.”

This content was produced with the assistance of AI translation services.